Trial Profile
Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil
- Indications Advanced breast cancer; Breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms ETNA
- 19 Jan 2024 Status changed from active, no longer recruiting to completed.
- 30 Nov 2023 This trial has been completed in Germany (Date of the global end of the trial: 16-Nov-2023), according to the European Clinical Trials Database record.
- 12 Aug 2023 This trial has been discontinued in Italy (Date of the global end of the trial: 28-Feb-2023), according to the European Clinical Trials Database record.